Literature DB >> 19001625

Nonfasting triglycerides and risk of ischemic stroke in the general population.

Jacob J Freiberg1, Anne Tybjaerg-Hansen, Jan Skov Jensen, Børge G Nordestgaard.   

Abstract

CONTEXT: The role of triglycerides in the risk of ischemic stroke remains controversial. Recently, a strong association was found between elevated levels of nonfasting triglycerides, which indicate the presence of remnant lipoproteins, and increased risk of ischemic heart disease.
OBJECTIVE: To test the hypothesis that increased levels of nonfasting triglycerides are associated with ischemic stroke in the general population. DESIGN, SETTING, AND PARTICIPANTS: The Copenhagen City Heart Study, a prospective, Danish population-based cohort study initiated in 1976, with follow-up through July 2007. Participants were 13,956 men and women aged 20 through 93 years. A cross-sectional study included 9637 individuals attending the 1991-1994 examination of the prospective study. MAIN OUTCOME MEASURES: Prospective study: baseline levels of nonfasting triglycerides, other risk factors at baseline and at follow-up examinations, and incidence of ischemic stroke. Cross-sectional study: levels of nonfasting triglycerides, levels of remnant cholesterol, and prevalence of ischemic stroke.
RESULTS: Of the 13,956 participants in the prospective study, 1529 developed ischemic stroke. Cumulative incidence of ischemic stroke increased with increasing levels of nonfasting triglycerides (log-rank trend, P < .001). Men with elevated nonfasting triglyceride levels of 89 through 176 mg/dL had multivariate-adjusted hazard ratios (HRs) for ischemic stroke of 1.3 (95% CI, 0.8-1.9; 351 events); for 177 through 265 mg/dL, 1.6 (95% CI, 1.0-2.5; 189 events); for 266 through 353 mg/dL, 1.5 (95% CI, 0.9-2.7; 73 events); for 354 through 442 mg/dL, 2.2 (95% CI, 1.1-4.2; 40 events); and for 443 mg/dL or greater, 2.5 (95% CI, 1.3-4.8; 41 events) vs men with nonfasting levels less than 89 mg/dL (HR, 1.0; 85 events) (P < .001 for trend). Corresponding values for women were 1.3 (95% CI, 0.9-1.7; 407 events), 2.0 (95% CI, 1.3-2.9; 135 events), 1.4 (95% CI, 0.7-2.9; 26 events), 2.5 (95% CI, 1.0-6.4; 13 events), and 3.8 (95% CI, 1.3-11; 10 events) vs women with nonfasting triglyceride levels less than 89 mg/dL (HR, 1.0; 159 events) (P < .001 for trend). Absolute 10-year risk of ischemic stroke ranged from 2.6% in men younger than 55 years with nonfasting triglyceride levels of less than 89 mg/dL to 16.7% in men aged 55 years or older with levels of 443 mg/dL or greater. Corresponding values in women were 1.9% and 12.2%. In the cross-sectional study, men with a previous ischemic stroke vs controls had nonfasting triglyceride levels of 191 (IQR, 131-259) mg/dL vs 148 (IQR, 104-214) mg/dL (P < .01); corresponding values for women were 167 (IQR, 121-229) mg/dL vs 127 (IQR, 91-181) mg/dL (P < .05). For remnant cholesterol, corresponding values were 38 (IQR, 26-51) mg/dL vs 29 (IQR, 20-42) mg/dL in men (P < .01) and 33 (IQR, 24-45) mg/dL vs 25 (IQR, 18-35) mg/dL in women (P < .05).
CONCLUSION: In this study population, nonfasting triglyceride levels were associated with risk of ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001625     DOI: 10.1001/jama.2008.621

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  148 in total

1.  Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease.

Authors:  Yating Wang; Li Shen; Danyan Xu
Journal:  Clin Cardiol       Date:  2018-12-21       Impact factor: 2.882

2.  Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia.

Authors:  H Carlijne Hassing; Hans Mooij; Shuling Guo; Brett P Monia; Keyang Chen; Wim Kulik; Geesje M Dallinga-Thie; Max Nieuwdorp; Erik S G Stroes; Kevin Jon Williams
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

3.  Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women.

Authors:  Jeffrey S Berger; Aileen P McGinn; Barbara V Howard; Lewis Kuller; Joann E Manson; Jim Otvos; J David Curb; Charles B Eaton; Robert C Kaplan; John K Lynch; Daniel M Rosenbaum; Sylvia Wassertheil-Smoller
Journal:  Stroke       Date:  2012-02-02       Impact factor: 7.914

Review 4.  Translational approaches to understanding metabolic dysfunction and cardiovascular consequences of obstructive sleep apnea.

Authors:  Luciano F Drager; Vsevolod Y Polotsky; Christopher P O'Donnell; Sergio L Cravo; Geraldo Lorenzi-Filho; Benedito H Machado
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-07-31       Impact factor: 4.733

5.  Risk of Ischemic Stroke Increases Over the Spectrum of Metabolic Syndrome Severity.

Authors:  Mark D DeBoer; Stephanie L Filipp; Mario Sims; Solomon K Musani; Matthew J Gurka
Journal:  Stroke       Date:  2020-06-19       Impact factor: 7.914

6.  What intervention trials don't tell us: the residual risk in primary prevention.

Authors:  Claudio Cimminiello
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 7.  [Severe hypertriglyceridemia : Diagnostics and new treatment principles].

Authors:  U Kassner; M Dippel; E Steinhagen-Thiessen
Journal:  Internist (Berl)       Date:  2017-08       Impact factor: 0.743

8.  Brief oral stimulation, but especially oral fat exposure, elevates serum triglycerides in humans.

Authors:  Richard D Mattes
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-12       Impact factor: 4.052

9.  Effect of chronic intermittent hypoxia on triglyceride uptake in different tissues.

Authors:  Qiaoling Yao; Mi-Kyung Shin; Jonathan C Jun; Karen L Hernandez; Neil R Aggarwal; Jason R Mock; Jason Gay; Luciano F Drager; Vsevolod Y Polotsky
Journal:  J Lipid Res       Date:  2013-02-05       Impact factor: 5.922

10.  Chronic intermittent hypoxia induces atherosclerosis via activation of adipose angiopoietin-like 4.

Authors:  Luciano F Drager; Qiaoling Yao; Karen L Hernandez; Mi-Kyung Shin; Shannon Bevans-Fonti; Jason Gay; Thomas E Sussan; Jonathan C Jun; Allen C Myers; Gunilla Olivecrona; Alan R Schwartz; Nils Halberg; Philipp E Scherer; Gregg L Semenza; David R Powell; Vsevolod Y Polotsky
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.